About inhibrx biosciences inc - INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
INBX At a Glance
Inhibrx Biosciences, Inc.
11025 North Torrey Pines Road
La Jolla, California 92037
| Phone | 1-858-795-4220 | Revenue | 1.30M | |
| Industry | Biotechnology | Net Income | -140,055,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 550.0% | |
| Fiscal Year-end | 12 / 2026 | Employees | 110 | |
| View SEC Filings |
INBX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 941.133 |
| Price to Book Ratio | 144.079 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.101 |
| Enterprise Value to Sales | 927.896 |
| Total Debt to Enterprise Value | 0.089 |
INBX Efficiency
| Revenue/Employee | 11,818.182 |
| Income Per Employee | -1,273,227.273 |
| Receivables Turnover | 7.345 |
| Total Asset Turnover | 0.008 |
INBX Liquidity
| Current Ratio | 3.93 |
| Quick Ratio | 3.93 |
| Cash Ratio | 3.675 |
INBX Profitability
| Gross Margin | -91.00 |
| Operating Margin | -10,386.538 |
| Pretax Margin | -10,773.308 |
| Net Margin | -10,773.462 |
| Return on Assets | -85.596 |
| Return on Equity | -197.85 |
| Return on Total Capital | -121.782 |
| Return on Invested Capital | -110.84 |
INBX Capital Structure
| Total Debt to Total Equity | 1,338.821 |
| Total Debt to Total Capital | 93.05 |
| Total Debt to Total Assets | 73.057 |
| Long-Term Debt to Equity | 1,309.721 |
| Long-Term Debt to Total Capital | 91.027 |